Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

@article{Polack2020SafetyAE,
  title={Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine},
  author={Fernando P. Polack and Stephen J. Thomas and Nicholas R E Kitchin and Judith Absalon and Alejandra C Gurtman and Stephen Lockhart and John L. Perez and Gonzalo P{\'e}rez Marc and Edson Duarte Moreira and Cristiano A F Zerbini and Ruth Bailey and Kena A. Swanson and Satrajit Roychoudhury and Kenneth J. Koury and Ping Li and Warren Vincent Kalina and David Cooper and Robert W. Frenck and Laura L. Hammitt and {\"O}zlem T{\"u}reci and Haylene Nell and Axel Schaefer and Serhat {\"U}nal and Dina B Tresnan and Susan H. Mather and Philip R. Dormitzer and Uğur Şahin and Kathrin U. Jansen and William C Gruber},
  journal={The New England Journal of Medicine},
  year={2020}
}
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2… 

Figures and Tables from this paper

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

With up to 6 months of follow-up and despite a gradually declining trend in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing COVID-19.

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

A two-dose regimen of the NVX-CoV2373 vaccine administered to adult participants conferred 89.7% protection against SARS- CoV-2 infection and showed high efficacy against the B.1.7 variant.

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.7 variant, and had a reassuring safety profile.

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

NVX-CoV2373 was well tolerated and demonstrated a high overall VE (>90%) for prevention of Covid-19, with most cases due to variant strains.

Antibody Response After a Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Liver Transplant Recipients

Dear Editors, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, and the World Health Organization declared a pandemic on

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

A global, randomized, placebo-controlled, phase 1–2–3 pivotal trial in which two 30-μg doses of BNT162b2 were administered 21 days apart found that waning immunity and viral diversification create a possible need for a third vaccine dose.

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed.

COMPARATIVE IMMUNOGENICITY OF BNT162b2 mRNA VACCINE WITH NATURAL COVID-19 INFECTION

This study proves the high immunogenicity of BNT162b2 vaccine although its sustainability remains to be seen, and uses comparative data from natural infection serological panels, expressing the clinical heterogeneity of natural infection may facilitate early decisions for vaccine evaluation in clinical trials.

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

A single immunization with Ad26.COV2.S induced rapid binding and neutralization antibody responses as well as cellular immune responses in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and Cellular immune responses.

BNT162b2 mRNA COVID-19 Vaccine: First Approval

This article summarizes the milestones in the development of BNT162b2 leading to these first approvals for the prevention of COVID-19 and conditional marketing authorizations in Switzerland and the EU.
...

References

SHOWING 1-10 OF 13 REFERENCES

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19.

Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.

In this head-to-head comparison, older adults receiving enhanced vaccines showed improved humoral and cell-mediated immune responses, compared to standard-dose vaccine recipients.

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

The results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases.

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

It is found that mRNAs containing pseudouridines have a higher translational capacity than unmodified m RNAs when tested in mammalian cells and lysates or administered intravenously into mice at 0.015-0.15 mg/kg doses.

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

COVID-19 Dashboard

Buscando elucidar as motivações que sustentam essa narrativa, o presente artigo teórico objetivou debater alguns dos argumentos utilizados para defendê-la, de modo a problematizar suas matrizes e

The Incubation Period of Coronavirus Disease 2019 (COVID-19) The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and From Publicly Reported Confirmed Cases: Estimation and Application Application

    Prospects for a safe COVID-19 vaccine

    Evaluated research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease finds neither principles of immunity nor preclinical studies provide a basis for prioritizing among the CO VID-19 vaccine candidates with respect to safety.